Studies using the OX40 agonist in combination with either anti-4-1BB, anti-PD-L1, anti-CTLA-4, and immunization in sarcoma, melanoma, hepatoma, and breast cancer models have shown significant survival benefit by boosting the T-cell response [106–109]. Here, CTLA4 is linked to melanoma.